Excerpt: “On June 15, 2018, the Subcommittee on Oversight and Investigations held a hearing on bio-preparedness. The FDA Chief Scientist testified at that hearing, including about the FDA OLSS. During the hearing, the FDA Chief Scientist acknowledged that, although the FDA has about 2,800 laboratory spaces, the OLSS had not conducted any inspections of these spaces over the last year. Further, the Chief Scientist testified that OLSS had only three permanent staff, not the 13 FTEs that the FDA had committed for OLSS in a September 2016 letter to the Committee.”
To view the letter, click here.